{"id":502534,"date":"2020-08-17T13:28:01","date_gmt":"2020-08-17T13:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=502534"},"modified":"2020-08-17T13:28:01","modified_gmt":"2020-08-17T13:28:01","slug":"acute-gout-flare-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-gout-flare-market-size-share-trends-epidemiology-forecast-till-2030_502534.html","title":{"rendered":"Acute Gout Flare Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Acute gout Flare Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute gout Flare , historical and forecasted epidemiology as well as the Acute gout Flare market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Gout is a systemic disease, which results from the deposition of monosodium urate crystals (MSU) in tissues.<\/p>\n

 <\/p>\n

Acute gout Flare market<\/strong><\/a> <\/a>report provides current treatment practices, emerging drugs, Acute gout Flare market share of the individual therapies, current and forecasted Acute gout Flare market Size from 2017 to 2030 segmented by seven major markets.<\/p>\n

 <\/p>\n

Acute gout flares are characterized by distinct inflammatory symptoms (e.g., pain, erythema, swelling), and may cause physical disability, as well as decreased quality of life. Therefore, rapid reduction of auto-inflammation to achieve prompt symptom control is the main goal in managing acute gout. Colchicine, NSAIDs, and glucocorticosteroids are recommended first-line treatment agents for acute gouty flares. The 2016 updated EULAR guidelines recommend considering treatment with an IL-1 inhibitor in patients having frequent flares and in those who are difficult to treat using conventional therapies. Canakinumab is currently the only IL-1 inhibitor that has been registered in Europe for the treatment of gout. <\/p>\n

Current guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) advise that long-term urate-lowering therapy (ULT), with the aim of maintaining serum urate levels (generally below 6 mg\/dL), is key to effective control of gout and should be initiated in the presence of certain clinical features: for example, tophi, frequent gouty attacks (flares; two or more per year), and urate arthropathy.<\/p>\n

 <\/p>\n

Effective options for the treatment of the acute attack include non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids and systemic corticosteroid therapy. With respect to efficacy (although not toxicity) the rapidity with which therapy is commenced appears to be more important than which medication is used. The best choice is often determined by whether or not there are contraindications to NSAID use, such as renal or cardiac insufficiency or a history of peptic ulceration.<\/p>\n

 <\/p>\n

Provided synovial fluid has been sent for analysis, including culture, it is reasonable to administer intra-articular corticosteroid immediately following joint aspiration (without removing the needle from the joint) when gout appears likely, even though sepsis has not yet been excluded. Systemic corticosteroid therapy can be provided as oral prednisone 20–40 mg daily in divided doses reducing to zero in 10–14 days or intramuscular depot tetracosactrin 1 mg, a synthetic analog of ACTH.<\/p>\n

 <\/p>\n

 <\/p>\n

Colchicine used as the primary treatment of the acute attack is associated with a very high rate of gastrointestinal toxicity. <\/p>\n

 <\/p>\n

Scope of the Report<\/strong><\/p>\n

• The report covers the descriptive overview of Acute gout Flare , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/p>\n

• Comprehensive insight has been provided into the Acute gout Flare epidemiology and treatment in the 7MM<\/p>\n

• Additionally, an all-inclusive account of both the current and emerging therapies for Acute gout Flare are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/p>\n

• A detailed review of Acute gout Flare market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/p>\n

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute gout Flare market<\/p>\n

 <\/p>\n

Request for sample pages<\/strong><\/a>
Table of contents<\/strong><\/a><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Acute gout Flare<\/p>\n

3. Competitive Intelligence Analysis for Acute gout Flare<\/p>\n

4. Acute gout Flare : Market Overview at a Glance<\/p>\n

4.1. Acute gout Flare Total Market Share (%) Distribution in 2017<\/p>\n

4.2. Acute gout Flare Total Market Share (%) Distribution in 2030<\/p>\n

5. Acute gout Flare : Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.2. Sign and Symptoms <\/p>\n

5.3. Pathophysiology <\/p>\n

5.4. Risk Factors <\/p>\n

5.5. Diagnosis <\/p>\n

6. Patient Journey<\/p>\n

7. Acute gout Flare Epidemiology and Patient Population<\/p>\n

7.1. Epidemiology Key Findings<\/p>\n

7.2. Assumptions and Rationale: 7MM<\/p>\n

7.3. Epidemiology Scenario: 7MM<\/p>\n

7.3.1. Acute gout Flare Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n

7.4. United States Epidemiology<\/p>\n

7.4.1. Acute gout Flare Epidemiology Scenario in the United States (2017-2030)<\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/p>\n

7.5.1. Germany Epidemiology<\/p>\n

7.5.1.1. Acute gout Flare Epidemiology Scenario in Germany (2017-2030)<\/p>\n

7.5.2. France Epidemiology<\/p>\n

7.5.2.1. Acute gout Flare Epidemiology Scenario in France (2017-2030)<\/p>\n

7.5.3. Italy Epidemiology<\/p>\n

7.5.3.1. Acute gout Flare Epidemiology Scenario in Italy (2017-2030)<\/p>\n

7.5.4. Spain Epidemiology<\/p>\n

7.5.4.1. Acute gout Flare Epidemiology Scenario in Spain (2017-2030)<\/p>\n

7.5.5. United Kingdom Epidemiology<\/p>\n

7.5.5.1. Acute gout Flare Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n

7.5.6. Japan Epidemiology<\/p>\n

7.5.6.1. Acute gout Flare Epidemiology Scenario in Japan (2017-2030)<\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Acute gout Flare Treatment and Management<\/p>\n

8.2. Acute gout Flare Treatment Algorithm <\/p>\n

9. Unmet Needs<\/p>\n

10. Key Endpoints of Acute gout Flare Treatment<\/p>\n

11. Marketed Products<\/p>\n

11.1. List of Marketed Products in the 7MM<\/p>\n

11.2. Drug Name: Company Name<\/p>\n

11.2.1. Product Description<\/p>\n

11.2.2. Regulatory Milestones<\/p>\n

11.2.3. Other Developmental Activities<\/p>\n

11.2.4. Pivotal Clinical Trials<\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/p>\n

List to be continued in report<\/p>\n

12. Emerging Therapies<\/p>\n

12.1. Key Cross<\/p>\n

12.2. Drug Name: Company Name<\/p>\n

12.2.1. Product Description<\/p>\n

12.2.2. Other Developmental Activities<\/p>\n

12.2.3. Clinical Development<\/p>\n

12.2.4. Safety and Efficacy<\/p>\n

12.2.5. Product Profile<\/p>\n

List to be continued in report<\/p>\n

13. Acute gout Flare : Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/p>\n

13.2. Acute gout Flare Market Size in 7MM<\/p>\n

13.3. Acute gout Flare Market Size by Therapies in the 7MM<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

15.1. United States: Market Size<\/p>\n

15.1.1. Acute gout Flare Total Market Size in the United States<\/p>\n

15.1.2. Acute gout Flare Market Size by Therapies in the United States<\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/p>\n

15.3. Germany Market Size<\/p>\n

15.3.1. Acute gout Flare Total Market Size in Germany<\/p>\n

15.3.2. Acute gout Flare Market Size by Therapies in Germany<\/p>\n

15.4. France Market Size<\/p>\n

15.4.1. Acute gout Flare Total Market Size in France<\/p>\n

15.4.2. Acute gout Flare Market Size by Therapies in France<\/p>\n

15.5. Italy Market Size<\/p>\n

15.5.1. Acute gout Flare Total Market Size in Italy<\/p>\n

15.5.2. Acute gout Flare Market Size by Therapies in Italy<\/p>\n

15.6. Spain Market Size<\/p>\n

15.6.1. Acute gout Flare Total Market Size in Spain<\/p>\n

15.6.2. Acute gout Flare Market Size by Therapies in Spain<\/p>\n

15.7. United Kingdom Market Size<\/p>\n

15.7.1. Acute gout Flare Total Market Size in the United Kingdom<\/p>\n

15.7.2. Acute gout Flare Market Size by Therapies in the United Kingdom<\/p>\n

15.8. Japan Market Outlook<\/p>\n

15.8.1. Japan Market Size<\/p>\n

15.8.2. Acute gout Flare Total Market Size in Japan<\/p>\n

15.8.3. Acute gout Flare Market Size by Therapies in Japan<\/p>\n

16. Access and Reimbursement Overview of Acute gout Flare<\/p>\n

17. KOL Views<\/p>\n

18. Market Drivers<\/p>\n

19. Market Barriers<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

*The table of contents is not exhaustive; the final content may vary. <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Acute gout Flare Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute gout Flare , historical and forecasted epidemiology as well as the Acute gout Flare market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-502534","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=502534"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=502534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=502534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=502534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}